- Home
- Apac Lymphedema Treatment Market
APAC Lymphedema Treatment Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-155 | No of pages: 218 | Format:
Asia-Pacific lymphedema treatment market is projected to register a substantial CAGR of 11.4% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029.
Market Segmentation:
Asia-Pacific Lymphedema Treatment Market, Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy, Others), Type (Secondary Lymphedema, Primary Lymphedema), Affected Area (Lower Extremity, Upper Extremity, Genitalia), Age Group (Adult, Geriatric, Pediatric), Route of Administration (Oral, Injectable, Topical), End User (Hospital, Speciality Clinics, Ambulatory Surgical Centers, Others) Distribution Channel (Pharmacy Stores, Direct Tender, Others) Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and Rest of Asia-Pacific) Industry Trends and Forecast to 2029
Some of the factors that drives the growth of the Asia-Pacific lymphedema treatment market are:
Rising prevalence of the diseases
Increasing healthcare expenditure
Market Players:
The key market players for Asia-Pacific lymphedema treatment market are listed below:
medi GmbH & Co. KG
PAUL HARTMANN AG
3M
Convatec Inc.
JUZO
SIGVARIS GROUP
Cardinal Health
Essity (BSN medical GmbH)
Smith+Nephew
HERANTIS PHARMA Plc
Huntleigh Healthcare Limited
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 43
1.1 OBJECTIVES OF THE STUDY 43
1.2 MARKET DEFINITION 43
1.3 OVERVIEW OF ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET 43
1.4 LIMITATIONS 45
1.5 MARKETS COVERED 45
2 MARKET SEGMENTATION 48
2.1 MARKETS COVERED 48
2.2 GEOGRAPHICAL SCOPE 49
2.3 YEARS CONSIDERED FOR THE STUDY 50
2.4 CURRENCY AND PRICING 50
2.5 DBMR TRIPOD DATA VALIDATION MODEL 51
2.6 MULTIVARIATE MODELLING 54
2.7 PRODUCT TYPE LIFELINE CURVE 55
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 55
2.9 DBMR MARKET POSITION GRID 57
2.10 MARKET APPLICATION COVERAGE GRID 58
2.11 VENDOR SHARE ANALYSIS 59
2.12 SECONDARY SOURCES 60
2.13 ASSUMPTIONS 60
3 EXECUTIVE SUMMARY 61
4 PREMIUM INSIGHTS 65
4.1 PESTEL'S ANALYSIS 67
4.2 PORTER'S MODEL 68
5 PIPELINE ANALYSIS FOR ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET 69
6 EPIDEMIOLOGY 70
7 REGULATORY GUIDELINES FOR ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET 71
7.1 U.S. 71
7.2 EUROPE 72
7.3 INDIA 72
7.4 MEXICO 73
7.5 CANADA 73
8 MARKET OVERVIEW 75
8.1 DRIVERS 77
8.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES ASIA PACIFICLY 77
8.1.2 INCREASE IN THE PREVALENCE OF CANCERS 77
8.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES 78
8.1.4 MULTIPLE THERAPIES 78
8.2 RESTRAINTS 79
8.2.1 HIGH COST OF TREATMENT 79
8.2.2 LACK OF AWARENESS ABOUT THE DISEASE 80
8.3 OPPORTUNITIES 80
8.3.1 DRUG APPROVALS 80
8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS 81
8.4 CHALLENGES 81
8.4.1 NO PERMANENT CURE FOR LYMPHEDEMA 81
8.4.2 DIFFICULT REIMBURSEMENT 82
9 IMPACT OF COVID-19 ON THE ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET 83
9.1 IMPACT ON PRICE 83
9.2 IMPACT ON DEMAND 83
9.3 IMPACT ON SUPPLY CHAIN 84
9.4 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS 84
9.5 CONCLUSION 84
10 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE 86
10.1 OVERVIEW 87
10.2 COMPRESSION THERAPY 90
10.2.1 BY PRODUCT 90
10.2.1.1 COMPRESSION PUMPS 90
10.2.1.2 COMPRESSION GARMENTS 90
10.2.1.2.1 COMPRESSION STOCKINGS 91
10.2.1.2.2 COMPRESSION SLEEVES 91
10.2.1.2.3 OTHERS 91
10.2.1.3 COMPRESSION BANDAGES & WRAPS 91
10.2.1.4 OTHERS 91
10.2.2 BY TECHNIQUE 92
10.2.2.1 STATIC COMPRESSION THERAPY 92
10.2.2.2 DYNAMIC COMPRESSION THERAPY 92
10.3 SURGERY 92
10.3.1 LYMPHOVENOUS TRANSPLANT 93
10.3.2 LYMPHATICOVENOUS ANASTOMOSIS 93
10.3.3 LIPOSUCTION 93
10.3.4 OTHERS 93
10.4 DRUG THERAPY 93
10.4.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) 94
10.4.2 RETINOIDS 94
10.4.3 ANTIBIOTICS 94
10.4.4 OTHERS 94
10.5 LASER THERAPY 95
10.6 OTHERS 96
11 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TYPE 97
11.1 OVERVIEW 98
11.2 SECONDARY LYMPHEDEMA 101
11.3 PRIMARY LYMPHEDEMA 101
11.3.1 LYMPHEDEMA PRAECOX (MEIGE DISEASE) 102
11.3.2 CONGENITAL LYMPHEDEMA 102
11.3.3 LYMPHEDEMA TARDA 102
12 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA 103
12.1 OVERVIEW 104
12.2 LOWER EXTREMITY 107
12.3 UPPER EXTREMITY 107
12.4 GENITALIA 108
13 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP 109
13.1 OVERVIEW 110
13.2 ADULT 113
13.3 GERIATRIC 113
13.4 PEDIATRIC 114
14 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 115
14.1 OVERVIEW 116
14.2 ORAL 119
14.3 INJECTABLE 119
14.4 TOPICAL 120
15 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY END USER 121
15.1 OVERVIEW 122
15.2 HOSPITAL 125
15.3 SPECIALTY CLINICS 125
15.4 AMBULATORY SURGICAL CENTERS 126
15.5 OTHERS 126
16 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 127
16.1 OVERVIEW 128
16.2 PHARMACY STORES 131
16.3 DIRECT TENDER 131
16.4 OTHERS 132
17 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY REGION 133
17.1 ASIA-PACIFIC 134
17.1.1 CHINA 143
17.1.2 JAPAN 147
17.1.3 INDIA 151
17.1.4 SOUTH KOREA 154
17.1.5 AUSTRALIA 158
17.1.6 INDONESIA 161
17.1.7 SINGAPORE 164
17.1.8 PHILIPPINES 167
17.1.9 THAILAND 171
17.1.10 MALAYSIA 174
17.1.11 VIETNAM 177
17.1.12 REST OF ASIA-PACIFIC 180
18 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: COMPANY LANDSCAPE 181
18.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 181
19 SWOT ANALYIS 182
20 COMPANY PROFILE 183
20.1 TACTILE MEDICAL 183
20.1.1 COMPANY SNAPSHOT 183
20.1.2 REVENUE ANALYSIS 183
20.1.3 COMPANY SHARE ANALYSIS 184
20.1.4 PRODUCT PORTFOLIO 184
20.1.5 RECENT DEVELOPMENT 184
20.1.6 CLINICAL TRIAL: 184
20.2 ESSITY (BSN MEDICAL GMBH) 185
20.2.1 COMPANY SNAPSHOT 185
20.2.2 COMPANY SHARE ANALYSIS 185
20.2.3 PRODUCT PORTFOLIO 185
20.2.4 RECENT DEVELOPMENT 186
20.3 3M 187
20.3.1 COMPANY SNAPSHOT 187
20.3.2 REVENUE ANALYSIS 187
20.3.3 COMPANY SHARE ANALYSIS 188
20.3.4 PRODUCT PORTFOLIO 188
20.3.5 RECENT DEVELOPMENTS 188
20.3.6 NEW BUSINESS SEGMENT 188
20.3.7 ACQUISITION 189
20.4 CARDINAL HEALTH 190
20.4.1 COMPANY SNAPSHOT 190
20.4.2 REVENUE ANALYSIS 190
20.4.3 COMPANY SHARE ANALYSIS 191
20.4.4 PRODUCT PORTFOLIO 191
20.4.5 RECENT DEVELOPMENT 191
20.5 LOHMANN & RAUSCHER GMBH & CO. KG 192
20.5.1 COMPANY SNAPSHOT 192
20.5.2 COMPANY SHARE ANALYSIS 192
20.5.3 PRODUCT PORTFOLIO 193
20.5.4 RECENT DEVELOPMENT 193
20.6 AIROS MEDICAL, INC. 194
20.6.1 COMPANY SNAPSHOT 194
20.6.2 PRODUCT PORTFOLIO 194
20.6.3 RECENT DEVELOPMENT 194
20.6.4 PRODUCT LAUNCH: 194
20.7 AVET PHARMACEUTICALS INC. 195
20.7.1 COMPANY SNAPSHOT 195
20.7.2 PRODUCT PORTFOLIO 195
20.7.3 RECENT DEVELOPMENT 195
20.8 BIOCOMPRESSION SYSTEMS 196
20.8.1 COMPANY SNAPSHOT 196
20.8.2 PRODUCT PORTFOLIO 196
20.8.3 RECENT DEVELOPMENT 197
20.8.4 AGREEMENT 197
20.9 CONVATEC INC. 198
20.9.1 COMPANY SNAPSHOT 198
20.9.2 PRODUCT PORTFOLIO 198
20.9.3 RECENT DEVELOPMENT 198
20.10 HERANTIS PHARMA PLC 199
20.10.1 COMPANY SNAPSHOT 199
20.10.2 RECENT DEVELOPMENT 199
20.11 HUNTLEIGH HEALTHCARE LIMITED 200
20.11.1 COMPANY SNAPSHOT 200
20.11.2 PRODUCT PORTFOLIO 200
20.11.3 RECENT DEVELOPMENT 200
20.12 JUZO 201
20.12.1 COMPANY SNAPSHOT 201
20.12.2 PRODUCT PORTFOLIO 201
20.12.3 RECENT DEVELOPMENT 201
20.13 KOYA MEDICAL 202
20.13.1 COMPANY SNAPSHOT 202
20.13.2 PRODUCT PORTFOLIO 202
20.13.3 RECENT DEVELOPMENT 202
20.13.4 APPROVAL 202
20.14 MEDI GMBH & CO. KG 203
20.14.1 COMPANY SNAPSHOT 203
20.14.2 PRODUCT PORTFOLIO 203
20.14.3 RECENT DEVELOPMENT 203
20.15 MEGO AFEK LTD 204
20.15.1 COMPANY SNAPSHOT 204
20.15.2 PRODUCT PORTFOLIO 204
20.15.3 RECENT DEVELOPMENT 205
20.15.4 APPLICATION LAUNCH: 205
20.16 PAUL HARTMANN AG 206
20.16.1 COMPANY SNAPSHOT 206
20.16.2 REVENUE ANALYSIS 206
20.16.3 PRODUCT PORTFOLIO 207
20.16.4 RECENT DEVELOPMENTS 207
20.17 SANYLEG SRL A SOCIO UNICO 208
20.17.1 COMPANY SNAPSHOT 208
20.17.2 PRODUCT PORTFOLIO 208
20.17.3 RECENT DEVELOPMENT 208
20.18 SIGVARIS GROUP 209
20.18.1 COMPANY SNAPSHOT 209
20.18.2 PRODUCT PORTFOLIO 209
20.18.3 RECENT DEVELOPMENTS 210
20.18.4 PRODUCT LAUNCHES: 210
20.19 SMITH +NEPHEW 211
20.19.1 COMPANY SNAPSHOT 211
20.19.2 REVENUE ANALYSIS 211
20.19.3 PRODUCT PORTFOLIO 212
20.19.4 RECENT DEVELOPMENT 212
20.20 THERMOTEK 213
20.20.1 COMPANY SNAPSHOT 213
20.20.2 PRODUCT PORTFOLIO 213
20.20.3 RECENT DEVELOPMENT 213
21 QUESTIONNAIRE 214
22 RELATED REPORTS 218
Segmentation
Short Description:
Asia-Pacific Lymphedema Treatment Market, By Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy and Others), Treatment (Primary Lymphedema and Secondary Lymphedema), Affected Area (Genital, Lower Extremity, Upper Extremity and Others), Age Group (Adult and Geriatric), Route of Administration (Oral, Injectable and Others), End User (Hospitals, Ambulatory Surgical Centres, Speciality Clinics and Others), Distribution Channel (Direct Tender, Pharmacy Stores, and Others), Country (Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines , Vietnam, and Rest of Asia-Pacific) Industry Trends and Forecast to 2029
Market Definition:
Lymphedema refers to swelling that generally occurs in upper and lower extremities. Sometimes both arms and both legs swell. Lymphedema is most commonly caused by the removal of or damage to lymph nodes as a part of cancer treatment. It results from a blockage in lymphatic system, which is part of immune system. Stems from a damaged lymphatic system, can lead to infections, disfigurement, debilitating pain and disability. There is no cure for lymphedema.
Lymphedema treatment involves multiple therapies instead of standard treatment, since the patients are dissatisfied or dont get cured with the conventional treatment of lymphedema. They approach the alternative treatment which offers more control over health care decisions, and the alternatives are found to be more compatible with the patients health system.
Lymphedema can occur after any cancer or its treatment that affects lymph node drainage. It has been reported to occur within days and up to 30 years after treatment for breast cancer. The initial stage lymphedema treatments are therapies, surgeries and lymphovenous transplant among others. But there is no permanent cure for lymphedema.
Market Segmentation:
Asia-Pacific lymphedema treatment market is categorized into seven notable segments which are by treatment type, type, affected area, age group, route of administration, end user, and distribution channel.
On the basis of treatment type, Asia-Pacific lymphedema treatment market is segmented in compression therapy, surgery, drug therapy, laser therapy and others
On the basis of type, Asia-Pacific lymphedema treatment market is segmented in primary lymphedema and secondary lymphedema
On the basis of affected area, Asia-Pacific lymphedema treatment market is segmented genital, lower extremity and upper extremity
On the basis of age group, the Asia-Pacific lymphedema treatment market is segmented into adult and geriatric
On the basis of route of administration, Asia-Pacific lymphedema treatment market is segmented in oral, injectable and others
On the basis of end user, Asia-Pacific lymphedema treatment market is segmented in hospitals, ambulatory surgical centres, speciality clinics and others
On the basis of distribution channel, Asia-Pacific lymphedema treatment market is segmented in direct tender, pharmacy stores and others
Market Players:
The key market players for the Asia-Pacific lymphedema treatment market are listed below:
Cardinal Health
Smith+Nephew
SIGVARIS GROUP
medi GmbH & Co. KG
PAUL HARTMANN AG
Convatec Inc.
3M
Juzo
Huntleigh Healthcare Limited
HERANTIS PHARMA Plc
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.